Why did the CSL share price go backwards in the March quarter?

Here’s how CSL performed over the first quarter of 2022.

| More on:
A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The CSL share price slipped 7.7% in the first quarter of 2022, closing March at $270.05
  • That's despite only seemingly good news having been released by the company
  • Over the three-month period, CSL released its half-year results and updated the market on its acquisition of Vifor Pharma

The CSL Limited (ASX: CSL) share price struggled through the March quarter despite plenty of good news being released by the company.

In fact, the biotechnology giant’s stock tumbled 7.76% last quarter, ending the period trading at $270.05.

For comparison, the S&P/ASX 200 Index (ASX: XJO) ended the quarter trading relatively flat with where it started, recording a gain of just 0.74%.

So, what moved the CSL share price over the three months ended 31 March? Let’s take a look.

What happened to the CSL share price last quarter?

The CSL share price had some notable ups and downs over the course of the March quarter.

The first came with the announcement of the completion of CSL’s share purchase plan on 14 February.

The share purchase plan – first announced in December – raised $750 million for CSL’s acquisition of Vifor Pharma.

The company received applications of $942.7 million for the capital raise, which offered new shares in the company for $253.57 apiece. As a result, it had to scale the offer back.

However, as The Motley Fool Australia’s James Mickleboro reported, the company was hit with a negative note from S&P Global Ratings that same day.

All in all, the CSL share price fell 1.99% on 14 February. Fortunately, it was soon boosted by the release of the company’s half-year results.

Over the six months ended 31 December, CSL’s revenue rose 5.3%, while its net profit after tax (NPAT) slipped 2.8%. The company’s dividend stayed at US$1.04 per share.

However, its bullish view on plasma collections and its financial year 2022 earnings likely helped lift the CSL share price.

It gained 8.51% on the day of its earnings’ release and a further 5.05% the following day.

The final piece of price-sensitive news released by the company last quarter dropped after the market closed on 3 March.

Then, CSL announced 74% of Vifor Pharma’s shares were tendered under a public tender offer.

That was slightly less than the company’s goal of 80%. Nevertheless, CSL said it would waive its acceptance rate condition and declare the offer successful.

Following the tender offer, CSL commenced a tender period for subsequent acceptance of the offer. As a result, the acquisition was on track to be finished by the middle of 2022.

The CSL share price gained just 0.31% on the news.

What else might have driven CSL’s stock last quarter?

That’s all the price-sensitive news released by CSL in the March quarter. However, there were a few more happenings that might have helped boost market sentiment toward its shares.

The company reportedly ditched efforts to create an antiviral treatment for COVID-19 in January. It will instead be focusing its $1 billion-a-year research program on other projects.

Additionally, CSL’s influenza vaccine was granted new approvals by regulators in March. As a result, it can now be administered to children above the age of two.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.
Healthcare Shares

Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

Read more »

A sad looking scientist sitting and upset about a share price fall.
Earnings Results

Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

Read more »

A man waking up happy with a smile on his face and arms outstretched representing the hefty Adairs dividend yield
Earnings Results

ResMed share price on watch following solid FY22 growth

ResMed has released its full year results...

Read more »

Female doctor with a mask holds out hand in a stop gesture.
Capital Raising

Up 90% in 2 weeks, here’s why the Paradigm share price has been halted

The biopharmaceutical company is planning a capital raise.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Broker Notes

Goldman Sachs gives its verdict on the CSL share price

Where next for CSL's shares?

Read more »

Healthcare Shares

Mayne Pharma share price rockets 25% on $680 million payday

It's been a good day for the ASX pharmaceutical company.

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

What’s with the Polynovo share price on Wednesday?

Shares in the ASX medical devices company hit their year to date high today before retreating again.

Read more »

A man in a wheelchair stretches both arms into the air in success.
Healthcare Shares

Imugene share price lifts 11% on clinical trial update

Imugene shares are flying higher today.

Read more »